<DOC>
	<DOCNO>NCT00005591</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , cetuximab , locate tumor cell either kill deliver tumor-killing substance without harm normal cell . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining chemotherapy monoclonal antibody therapy may kill tumor cell . PURPOSE : Phase II trial study effectiveness cetuximab plus gemcitabine treating patient locally advance , metastatic , recurrent cancer pancreas .</brief_summary>
	<brief_title>Cetuximab Plus Gemcitabine Treating Patients With Locally Advanced , Metastatic , Recurrent Cancer Pancreas</brief_title>
	<detailed_description>OBJECTIVES : I . Determine objective response , time progression , survival , clinical benefit response , quality life patient locally advance , metastatic , recurrent adenocarcinoma pancreas treat cetuximab gemcitabine . II . Determine safety toxicity profile regimen patient population . OUTLINE : This multicenter study . Patients receive test dose cetuximab IV 10 minute follow 30 minute observation period . Following observation , patient receive load dose cetuximab IV 1-2 hour follow 1 hour later gemcitabine IV 30 minute weekly 7 week . Following 1 week rest , patient stable respond disease continue treatment maximum 6 month . During subsequent course , patient receive maintenance dos cetuximab IV 1 hour weekly 8 week . Gemcitabine IV administer 30 minute weekly 3 week , follow 1 week rest , repeat total treatment course 8 week . Treatment continue absence unacceptable toxicity disease progression . Quality life assess baseline , course therapy , 3 month therapy . Patients follow every 3 month evidence disease progression . PROJECTED ACCRUAL : A minimum 40 patient accrue study within 8 month .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm locally advanced , metastatic , recurrent adenocarcinoma pancreas amenable curative surgical resection Immunohistochemical evidence EGFr expression 1+ great Measurable disease No history treat active brain metastasis carcinomatous meningitis PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : Not specify Hematopoietic : WBC least 3,000/mm3 Hemoglobin least 9 g/dL Platelet count least 100,000/mm3 No unstable coagulation disorder Hepatic : AST/ALT great 5 time upper limit normal ( ULN ) Alkaline phosphatase great 5 time ULN Bilirubin great 2 time ULN Renal : Creatinine great 2.5 mg/dL Cardiovascular : No uncontrolled hypertension arrhythmia No unstable congestive heart failure Neurologic : No uncontrolled seizure disorder No active neurological disease Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No concurrent unstable medical condition ( e.g. , uncontrolled diabetes mellitus active infection require systemic antibiotic , antiviral , antifungal ) PRIOR CONCURRENT THERAPY : Biologic therapy : No prior murine monoclonal antibody therapy No prior cetuximab Chemotherapy : No prior chemotherapy advance pancreatic cancer Prior adjuvant chemotherapy follow complete surgical resection allow provided cancer recurrence first document 6 month completion treatment Endocrine therapy : Not specify Radiotherapy : At least 4 week since prior radiotherapy recover No prior radiotherapy site measurable disease unless documented disease progression since prior irradiation Surgery : Prior surgical resection allow Other : At least 4 week since prior investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>recurrent pancreatic cancer</keyword>
	<keyword>adenocarcinoma pancreas</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
</DOC>